CCEL — Q3 2026 Financial Report Analysis

Profit jumps 70% on flat sales, but fewer new families are signing up

Cryo-Cell International stores umbilical cord blood and cord tissue (sources of stem cells) for families who pay to keep them frozen in case a child or relative needs them later. In its fiscal third quarter (the three months to August 31, 2026; Cryo-Cell's fiscal year ends November 30), revenue was $7.82 million, unchanged from a year earlier to within $1,300. Net income still rose 70% to $1.27 million, or $0.16 per diluted share vs $0.09. The gain came from lower processing costs, a swing from losses to gains on the company's stock investments, lower bank interest and a lower tax rate. It did not come from growth. The number of new babies whose cord blood Cryo-Cell processed fell 16%.

At a glance

• Revenue: $7.82M, 0.0% YoY. Fees from existing customers renewing storage grew 3%, but that only cancelled out a 16% fall in new US cord blood specimens processed.
• Operating margin: 28.0% vs 24.3%. This is the share of revenue left after running the business, before interest and tax. It rose because processing fewer new samples cut cost of sales 10%, and SG&A fell 3% even with higher legal bills.
• Nine-month operating cash flow: $3.64M vs net income of $1.87M. Cash is ahead of profit because many families prepay for 18-year or lifetime storage. Cryo-Cell collects that money up front and books it as revenue over many years.

The quarter in numbers

n/d: the filing gives only the percentage change, not the underlying count or dollar amount. n/m: not meaningful (a very small base).

Year to date (nine months), the picture is weaker. Revenue fell 1.9% to $23.28M, and operating income fell 6.6% to $4.16M because of a $1.98M rise in legal fees from the Duke arbitration (below). Net income still rose 35% to $1.87M ($0.23 vs $0.17 per share), mostly because losses on marketable securities shrank from $0.60M to $0.10M and interest expense fell.

Takeaway: The 70% profit jump hides a shrinking pipeline of new customers. New-baby enrollments fell 16% in the quarter and 15% year to date, and existing customers' renewals (+3%) are only keeping revenue flat. Almost half the pre-tax profit improvement came from investment gains and lower interest, not from the core business.

Where the profit growth actually came from

Pre-tax income rose by about $639,000, from $1.19M to $1.83M. Broken down using the income statement:

About 41% of the improvement ($264,000) is a mark-to-market swing. Cryo-Cell holds about $2.8M of stocks, and their price changes run straight through the income statement. Last year's quarter had a loss on them and this year's had a gain, so this source can just as easily reverse next quarter.

The tax rate added a further lift. The effective rate (tax as a share of pre-tax profit) was 30.4% this quarter vs 36.8% a year ago. At last year's rate, net income would have been about $1.15M, or roughly $0.14 a share, not $0.16.

Buybacks played no part. Diluted shares were about 8.07 million in both periods, and the company repurchased no stock in the quarter.

Inside operations: cost of sales fell 10% to $1.61M, which the filing attributes to "the decrease in the number of new domestic cord blood specimens processed." That is a cost saving with a bad cause: fewer new customers means less lab work. Selling, general and administrative expenses (SG&A: sales, marketing, salaries and professional fees) fell 3% to $3.78M, even though legal fees rose $126,000. So spending outside legal fell by roughly $220,000. The small public cord blood bank sold $135,000 of units vs $4,000 a year ago. Management attributes this to "the volatility of customer demand," and the unit lost $25,000 at the operating level.

What the headline numbers hide

• Cash vs profit. Nine-month operating cash flow was $3.64M, about 1.9 times net income of $1.87M. The main reason is a $3.27M increase in deferred revenue: cash families prepaid for long-term storage that has not yet been counted as revenue. Total deferred revenue reached $63.97M, up from $60.70M at fiscal year-end. Operating cash flow was still down 13% from $4.20M a year earlier, partly because the company paid down $1.71M of accrued expenses.
• Bad debts are large. Cryo-Cell bills many annual-plan customers after the fact. The allowance for doubtful accounts (receivables it does not expect to collect) is $4.37M against $6.83M of net receivables, so roughly 39% of gross billings outstanding are reserved. The nine-month provision for bad debts rose to $0.92M from $0.78M. Receivables were flat over the nine months ($6.83M vs $6.85M), so they are not growing faster than sales.
• Some "interest" is really a revenue share. Of the $438,000 quarterly interest expense, $285,000 is paid to parties to old revenue-sharing agreements and is based on storage revenue collected. Only $153,000 relates to bank debt. Bank interest fell from $249,000 because the revolving credit line was repaid in full ($0 vs $2.3M at November 30, 2025). The term loan still has about $8.2M outstanding at 6.89%.
• No dividend this year. No dividends were paid in the first nine months of fiscal 2026, compared with $3.23M ($0.40 a share) in the same period of fiscal 2025. Spare cash went to paying down the credit line instead.
• The balance sheet shows negative equity. Total liabilities ($78.7M) exceed total assets ($62.3M), leaving a stockholders' deficit of $16.4M (improved from $18.6M). Most liabilities are deferred revenue, which is a service obligation rather than borrowed money. On the asset side, $23.6M (38% of total assets) is deferred tax assets, which only have value if the company keeps earning taxable profit.
• Listing risk. On March 9, 2026, NYSE American notified Cryo-Cell that it does not meet the exchange's continued-listing standards under Section 1003(a). The exchange accepted the company's compliance plan and gave it until September 9, 2027 to fix this. The 10-Q warns that Cryo-Cell "may need to raise additional capital to regain compliance." Any new shares issued would dilute existing shareholders.

The Duke arbitration: the biggest open question

In 2021 Cryo-Cell licensed Duke University's technology for cord blood and cord tissue infusion treatments (for conditions such as cerebral palsy and autism). It planned to build a clinic and a manufacturing business on that licence. It wrote off the full $13.1M carrying value of the licence in fiscal 2023. In October 2024 it filed for arbitration, claiming Duke fraudulently induced it into the agreement and breached it. Cryo-Cell has told Duke it believes damages exceed $100 million. Duke filed counterclaims for breach and indemnity, seeking unspecified damages, and terminated the licence as of May 17, 2025.

The final hearing ended in late July 2026. The filing gives two timelines for a ruling: "by the end of calendar year 2026" in the legal proceedings section and "early 2027" in Note 12. Management says Duke's counterclaims should not have a material adverse effect, but warns that an unfavourable outcome "could negatively and materially impact" the business. The company does not reserve for future legal fees. The planned Cryo-Cell Institute for Cellular Therapies and the spinoff of subsidiary Celle Corp. are both on hold, and the company says it is "unlikely" to get the licence's benefits.

With the hearing over, legal spending should fall from here: the quarterly rise in legal fees was only $126,000, compared with $1.98M for the nine months. That would lift reported operating income even if nothing else changed.

Outlook

Management gives no revenue or earnings guidance. It says its cash, marketable securities, operating cash flow and outside capital will cover "its known cash needs for at least the next 12 months." It also says future cash flow "will depend primarily upon increasing revenues" from cord blood and tissue storage.

Our read: the core economics are stable in the short term. About $64M of prepaid storage is already on the books, and annual renewals are growing 3%. The quarterly profit rate, however, is not a clean base to extrapolate from. The investment gain and the lower tax rate may not repeat. The underlying trend, new enrollments down 15-16%, steadily shrinks the base of future renewals.

Three things to watch:

1. The Duke ruling. A large award would change the balance sheet. A loss on the counterclaims would add costs.
2. Whether new-specimen volumes stabilise. This is the only real sign of growth for the core business.
3. How Cryo-Cell regains NYSE American compliance before the September 2027 deadline, in particular whether it issues new shares to do so.